From the newsletter

Africa is witnessing a surge in local vaccine research and development. The latest milestone is South Africa’s launch of the continent’s first-in-human clinical trial for a locally developed HIV vaccine. The BRILLIANT 011 study officially enrolled its first participants in February 2026 at the Desmond Tutu HIV Foundation in Cape Town.

  • The new vaccine induces broadly neutralising antibodies capable of targeting multiple HIV strains in Africa, an approach seen as critical in the search for an effective HIV vaccine. 

  • This milestone came just days before Kenya launched a World Health Organization-backed technology transfer programme to build local capacity in vaccine research and manufacturing.

More details

  • The HIV vaccine was developed by a consortium of scientists under the South African Medical Research Council, the Wits Health Consortium and the Desmond Tutu HIV Foundation. The BRILLIANT 011 study is a first-in-human, African-led clinical trial assessing the safety and immune response of the candidate vaccine in HIV-negative volunteers. It targets a specific region of the HIV envelope and includes an adjuvant designed to strengthen the body’s immune reaction.

  • The vaccine induces broadly neutralising antibodies capable of targeting multiple HIV strains, a long-standing scientific hurdle in HIV vaccine development. The trial is highly intensive, involving frequent blood sampling and advanced laboratory analysis, including single-cell and B-cell profiling, to closely track immune responses and guide further refinement of the vaccine design. If early results demonstrate a strong immune response, researchers plan to expand into larger trials. 

  • This milestone in South Africa came just days before Kenya launched a major initiative to strengthen its vaccine capacity. On 18 February 2026, Kenya launched a World Health Organization-backed technology transfer programme at a stakeholder event in Nairobi. Implemented through the Kenya BioVax Institute and KEMRI, the initiative aims to build local vaccine research and manufacturing capacity.

  • The programme is part of a global effort spanning fourteen countries, with African participants including South Africa, Egypt, Nigeria, Senegal and Tunisia. Six researchers from KBI and KEMRI have been trained to support the technology transfer. Partners at the launch included WHO, Medicines Patent Pool, ThermoFisher and the Pharmacy and Poisons Board.

  • African pharma struggles with high capital costs, fragmented regulations, limited clinical trials, dependence on imported ingredients and weak commercial reach. BRILLIANT 011 trial strengthens clinical research capacity and regulatory experience while Kenya’s WHO-backed technology transfer programme builds local production platforms.

Our take

  • African-led vaccines can be adapted to regional disease strains and epidemiology, making them potentially more effective than imported products. 

  • This could accelerate protection against both endemic and emerging diseases across the continent.

Keep Reading